In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...
Feb 12 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...
DexCom Inc. reports fourth-quarter earnings Thursday after the market close, with investors eager to gauge whether the continuous glucose monitoring leader can defend its premium market position ...
Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with Type 2 diabetes and your fit-fluencer friend. Jake Leach, who took over as Dexcom CEO today, wants ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...
Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. (Courtesy of Dexcom) This ...
Dexcom is facing a proposed class action lawsuit over problems with its flagship glucose sensor. The complaint, filed in the U.S. District Court for the Central District of California last week, ...
Dexcom CGM systems provide automatic blood glucose updates every five minutes. FreeStyle Libre sensors can last up to 15 days and no longer need frequent scanning for updates. Both Dexcom and ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results